Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, Observer-blind, Randomized, Controlled, Two-stage, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Response of the Trivalent Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) and Typhoid Fever in Healthy European and African Adults
Conditions
Interventions
Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose
Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose
+9 more
Locations
2
Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Blantyre, Malawi
Start Date
September 13, 2022
Primary Completion Date
September 2, 2024
Completion Date
January 7, 2025
Last Updated
November 28, 2025
NCT07286370
NCT02689193
NCT01608815
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions